2018
DOI: 10.1016/j.spinee.2018.05.003
|View full text |Cite
|
Sign up to set email alerts
|

Annular closure in lumbar microdiscectomy for prevention of reherniation: a randomized clinical trial

Abstract: In patients at high risk of herniation recurrence after lumbar microdiscectomy, annular closure with a bone-anchored implant lowers the risk of symptomatic recurrence and reoperation. Additional study to determine outcomes beyond 2 years with a bone-anchored annular closure device is warranted.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
89
0
4

Year Published

2018
2018
2021
2021

Publication Types

Select...
5
1

Relationship

2
4

Authors

Journals

citations
Cited by 76 publications
(96 citation statements)
references
References 25 publications
3
89
0
4
Order By: Relevance
“…Implants, such as Inclose or Xclose (ANULEX Technology, Minnetonka, Minnesota), have been developed, but are no longer available as they have caused several complications and clinical trials have suggested no significant benefits with regard to prevention of reherniation . At current, Barricaid (Intrinsic Therapeutics, Woburn, Massachusetts) is the only commercially available implant, for which a significant decrease in herniation recurrence risk could be observed up to 2 years after surgery . Nevertheless, Barricaid`s long‐term effects remain to be studied, in particular as Barricaid operates by bone anchors and because no in situ AF regeneration was evaluated.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Implants, such as Inclose or Xclose (ANULEX Technology, Minnetonka, Minnesota), have been developed, but are no longer available as they have caused several complications and clinical trials have suggested no significant benefits with regard to prevention of reherniation . At current, Barricaid (Intrinsic Therapeutics, Woburn, Massachusetts) is the only commercially available implant, for which a significant decrease in herniation recurrence risk could be observed up to 2 years after surgery . Nevertheless, Barricaid`s long‐term effects remain to be studied, in particular as Barricaid operates by bone anchors and because no in situ AF regeneration was evaluated.…”
Section: Discussionmentioning
confidence: 99%
“…30 At current, Barricaid (Intrinsic Therapeutics, Woburn, Massachusetts) is the only commercially available implant, 29 for which a significant decrease in herniation recurrence risk could be observed up to 2 years after surgery. 31 Nevertheless, Barricaid`s long-term effects remain to be studied, in for a large AF defect in bovine IVD within a bioreactor culture system, could limit the biomechanical deterioration resulting from the defect. 33 The observation period, however, was relatively short and although cell infiltration could be observed, it remains to be determined whether application of cell engraftment is required, especially considering the limited densities and potency of endemic IVD cells.…”
Section: Discussionmentioning
confidence: 99%
“…This study describes outcomes of the control group only, from a multicenter, prospective randomized trial of subjects that underwent microscopic limited lumbar discectomy (only the herniated part of the disc was removed) and were followed for 2 years [13]. This study retrospectively reviewed the prospective data to analyse the natural course of MC in serial imaging.…”
Section: Methodsmentioning
confidence: 99%
“…For the generation of random sequences, seven articles provide computer-generated random numbers or similar methods. Only one article in randomization hiding provides specific details (NCT01283438), 16 and six articles indicate the use of random number table or other random allocation scheme, but did not provide details. Two articles mentioned the article used blind, 12,16 and the other five articles do not mentioned the blind method; all articles describe the number and reasons for withdrawal.…”
Section: Quality Assessmentmentioning
confidence: 99%
“…Six studies provided available data in reoperation rate. [12][13][14][15][16]18 There was no significant heterogeneity (P > 0.1, I 2 = 7%), the fixed effect model was used for analysis. The pooled outcomes demonstrated that a 1.74fold higher risk of reoperation rate in the AF unrepaired group than in the repair group [RR = 1.74, 95% CI (1.22, 2.49), P = 0.002; Fig.…”
Section: Reoperation Ratementioning
confidence: 99%